Physician profile
Terry Lam Lu
NPI 1881379758
$1,591.58
in general payments reported to CMS, 2019-2025
11 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $93.70 · 2024: $465 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $323.27 | 2025 | Tryptyr, Hydrus Microstent, Voyager Dslt |
| Biotissue Holdings INC. | $292.17 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $220.67 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $150.31 | 2025 | Oxervate |
| Amgen INC. | $111.32 | 2024 | Tepezza |
| Bausch & Lomb Americas INC. | $102.76 | 2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $97.23 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $95.05 | 2024 | Acthar |
| Oyster Point Pharma, INC. | $93.70 | 2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $85.21 | 2024-2025 | Veritas Vision System, Tecnis Simplicity |
| Abbvie INC. | $19.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.